Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before
surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is
a specific mutation (change) in the BRAF gene, which makes a protein that is involved in
sending signals in cells and in cell growth. It may increase the growth and spread of tumor
cells. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Pembrolizumab, dabrafenib, and trametinib may
help to control BRAF V600E-mutated anaplastic thyroid cancer when given before surgery.